3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
2
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Breast
1
Conditions
Lung Neoplasms
3
Prostatic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Small Cell Lung Carcinoma
1
Radiation Pneumonitis
1
Radiation Fibrosis Syndrome
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pelvic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Malignant Solid Neoplasm
1
Malignant Primary Pelvic Neoplasm
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Heart Defects, Congenital
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8
1
Interventions
Cyclophosphamide
13
pembrolizumab
8
Brentuximab Vedotin
8
fludarabine
7
Nivolumab
7
Whole-Body Irradiation
6
Specimen Handling
6
Mycophenolic Acid
6
Gemcitabine
6
Etoposide
6
Doxorubicin
6
Dacarbazine
6
fludarabine phosphate
5
Vinblastine
5
Melphalan
5
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Dexamethasone
5
Stem Cell Transplantation
4
Cytarabine
4
Vinorelbine
3
Tacrolimus
3
Magnetic Resonance Spectroscopy
3
Cyclosporine
3
Carmustine
3
Blood Specimen Collection
3
thymoglobulin
2
polatuzumab vedotin
2
pegylated granulocyte colony-stimulating factor
2
pegfilgrastim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Hodgkin Disease
×
Exercise Test
×
Clear all
NCT05595577
2026-03-20
PALS
Wake Forest University Health Sciences
Phase NA
Recruiting
110 enrolled